Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma

Cellular immunotherapy is a rapidly progressing field in multiple myeloma (MM). Multiple clinical trials have reported impressive efficacy of B cell maturation antigen (BCMA) directed chimeric antigen receptor cell therapy (BCMA CART) in MM. While trials demonstrated a high response rate, the durable response rate is around 30%. Most patients lose their CART cells, and the disease relapses within the first year, suggesting an inhibition by the MM tumor microenvironment (TME). Therefore strategies to overcome this inhibition would represent a major advance in this field.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Reona Sakemura, Michelle J. Cox, Mehrdad Hefazi, Michael J. Hansen, Roman H. Khadka, Claudia Manriquez Roman, Kendall J. Schick, Erin E. Tapper, Paulina Horvei, Michael W. Ruff, Denise K. Walters, Sameer A. Parikh, Neil E. Kay, Saad S. Kenderian Tags: 333 Source Type: research